News coverage about Viveve Medical (NASDAQ:VIVE) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Viveve Medical earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.2443978695998 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the media stories that may have effected Accern Sentiment’s scoring:

A number of research analysts have recently commented on the company. B. Riley reaffirmed a “buy” rating and set a $10.00 price target on shares of Viveve Medical in a research report on Friday, May 12th. ValuEngine raised Viveve Medical from a “sell” rating to a “hold” rating in a research report on Friday, June 9th. Raymond James Financial, Inc. assumed coverage on Viveve Medical in a research report on Thursday, May 25th. They set an “outperform” rating and a $10.00 price target on the stock. Finally, Cowen and Company assumed coverage on Viveve Medical in a research report on Wednesday, May 3rd. They set an “outperform” rating and a $11.00 price target on the stock. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Viveve Medical presently has a consensus rating of “Buy” and a consensus target price of $13.25.

Shares of Viveve Medical (VIVE) traded up 1.20% on Tuesday, hitting $6.73. The stock had a trading volume of 51,743 shares. Viveve Medical has a 12 month low of $3.75 and a 12 month high of $11.16. The stock’s market cap is $130.25 million. The stock has a 50 day moving average of $7.30 and a 200-day moving average of $6.38.

Viveve Medical (NASDAQ:VIVE) last released its quarterly earnings results on Thursday, May 11th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.51) by $0.06. Viveve Medical had a negative net margin of 255.11% and a negative return on equity of 232.94%. The company had revenue of $3.04 million for the quarter, compared to the consensus estimate of $2.70 million. Equities research analysts anticipate that Viveve Medical will post ($1.81) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at

About Viveve Medical

Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.

Receive News & Ratings for Viveve Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical Inc. and related companies with's FREE daily email newsletter.